Last reviewed · How we verify
Hyperparathyroidism Secondary to Chronic Renal Failure
Approved treatments
- Zemplar · AbbVie
Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health. - Calcijex · Esjay Pharma
- Zemplar · Danderyd Hospital
- Rocaltrol · Shandong University
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hyperparathyroidism Secondary to Chronic Renal Failure patent landscape — cliff calendar, originator estates, attackable patents
- Hyperparathyroidism Secondary to Chronic Renal Failure treatment landscape brief
- Hyperparathyroidism Secondary to Chronic Renal Failure treatment updates RSS
Frequently asked questions about Hyperparathyroidism Secondary to Chronic Renal Failure
What drugs treat Hyperparathyroidism Secondary to Chronic Renal Failure?
Tracked treatments include Zemplar, Calcijex, Rocaltrol.
What is the treatment for Hyperparathyroidism Secondary to Chronic Renal Failure?
Standard treatment for Hyperparathyroidism Secondary to Chronic Renal Failure includes Zemplar, Calcijex, Rocaltrol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hyperparathyroidism Secondary to Chronic Renal Failure patent cliff · Hyperparathyroidism Secondary to Chronic Renal Failure CI report
- Treatment: Zemplar · AbbVie
- Treatment: Calcijex · Esjay Pharma
- Treatment: Zemplar · Danderyd Hospital
- Treatment: Rocaltrol · Shandong University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing